Frovatriptan

Systematic (IUPAC) name
(+)-(R)-3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
Identifiers
CAS number	158930-17-7
ATC code	N02CC07
PubChem	5284561
DrugBank	APRD00270
Chemical data
Formula	C14H17N3O
Mol. mass	243.304 g/mol
Synonyms	6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Pharmacokinetic data
Bioavailability	20-30%
Metabolism	Hepatic
Half life	26 hours
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	C: (USA) B3: (AUS)
Legal status	Prescription only
Routes	Oral

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.^[1]

[edit] Pharmacology

Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

[edit] US licensing

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,^[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).

[edit] Footnotes

[edit] External links

• Frova (manufacturer's website)
• Frovatriptan Succinate (patient information)
• FDA labeling

This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v • d • e